ipilimumab,nivolumab,canakinumab,cabozantinib
novartis,bms,exelixis
['cana ', 'nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', ' ipi ', 'cosmic313', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ipilimumab', 'cabo ', 'nivo', 'cosmic-313', 'bristol', 'exelixis']
outstanding update of #cosmic313 by ...still missing the explanation the high vs intermediate risk group dirences! ? #gu23 
Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert